使用国家癌症数据库对内膜瘤进行放射治疗的剂量
Melanie L Rose1,2, Erika Moen3,4, Bryan Ager5
1Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 03756, USA. melanie.l.rose@hitchcock.org.
Journal of neuro-oncology
|August 28, 2024
概括
更高的辅助放射治疗剂量并没有改善儿科内膜瘤的存活率. 然而,世界卫生组织2级瘤的整体存活率比3级要好,不论辐射剂量如何.
科学领域:
- 儿科瘤学 儿科瘤学
- 辐射瘤学 辐射瘤学
- 神经瘤学神经瘤学
背景情况:
- 内膜瘤是小儿大脑瘤的一个重要原因.
- 辅助放射治疗是一种标准治疗方法,但最佳剂量仍在争论中.
研究的目的:
- 研究辅助放射治疗对小儿内膜瘤生存的剂量依赖影响.
- 为了确定与更高辐射剂量的生存益处相关的患者和疾病特征.
主要方法:
- 从国家癌症数据库对世界卫生组织 (WHO) 2级或3级非转移性内膜瘤的数据分析.
- 包括接受手术切除并接受辅助放射治疗 (4500-6300 cGy) 的患者.
- 利用Cox比例危险比率和Kaplan-Meier估计来评估与辐射剂量和患者/瘤因素相关的整体存活率 (OS).
主要成果:
- 在接受≤5400cGy与>5400cGy的患者之间,没有观察到OS的显著差异.
- 卡普兰-梅尔曲线表明,基于一般队列,年龄,手术程度或瘤等级的辐射剂量,没有OS差异.
- 患有世卫组织2级瘤的患者与患有3级瘤的患者相比,无论辐射剂量如何,都显示出更好的生存状况.
结论:
- 辅助放射治疗剂量升级超过5400cGy并没有为儿科内膜瘤的生存带来好处.
- 世卫组织2级尾瘤与3级尾瘤相比,无论辐射剂量如何,都与更好的生存状况有关.
- 没有特定的患者或瘤亚组 (年龄,切除程度,等级) 从更高的辐射剂量中显示出差异性生存益处.
相关概念视频
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K